MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the management of small cell lung cancer using a virtual tumor board format. SCLC is an aggressive subtype of lung cancer, and for patients with advanced or extensive-stage disease, the current first-line standard of care is chemo-immunotherapy. For those who do not achieve long-term disease control, second-line options are somewhat limited. Dr. Liu, Dr. Blackhall, and Dr. Shields discuss currently available treatment options (platinum-retreatment, lurbinectedin, topotecan) and some promising drugs in development for SCLC.